Sydney, Australia, 13 December 2021: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced that Executive Chairman, Mr Paul Hopper, through associated family entities, has sold 75 million shares in an off-market block trade, to an institutional investor. Other details include: • The ordinary shares sold represent 1.3% of Imugene’s fully paid ordinary shares on issue and approximately 19% of Mr Hopper's. • This is the first significant sale made by Mr Hopper since founding the company 8 years ago • Mr Hopper obtained the necessary approvals pursuant to the company’s ‘Policy for Trading in Company Securities’ prior to entering into the sale. Mr Hopper said “As the Founder, Executive Chairman and largest shareholder of the Company, I remain committed to Imugene and I am very excited about its prospects. The sale relates to a portion of my exposure to Imugene, which remains substantial, and has become necessary due to my personal circumstances including portfolio balancing, estate planning for my family and taxation obligations. I look forward to continuing to drive success for the company and its shareholders.”
Can you please now stick to the facts.
IMU Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)